| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bronchiectasis | 17 | 2019 | 312 | 3.58 | Why? |
| Community-Acquired Infections | 10 | 2021 | 2328 | 0.92 | Why? |
| Pneumonia, Pneumococcal | 3 | 2019 | 251 | 0.90 | Why? |
| Head Protective Devices | 2 | 2020 | 163 | 0.84 | Why? |
| Residual Volume | 2 | 2018 | 45 | 0.82 | Why? |
| Streptococcus pneumoniae | 3 | 2019 | 827 | 0.76 | Why? |
| Continuous Positive Airway Pressure | 5 | 2021 | 1187 | 0.73 | Why? |
| Pneumonia, Bacterial | 4 | 2018 | 843 | 0.64 | Why? |
| Noninvasive Ventilation | 6 | 2021 | 2329 | 0.56 | Why? |
| Anti-Bacterial Agents | 10 | 2020 | 10083 | 0.53 | Why? |
| Respiratory Insufficiency | 9 | 2021 | 7301 | 0.45 | Why? |
| Hypoxia | 3 | 2021 | 3626 | 0.45 | Why? |
| Drug Resistance, Bacterial | 4 | 2019 | 1414 | 0.45 | Why? |
| Idiopathic Pulmonary Fibrosis | 2 | 2020 | 595 | 0.38 | Why? |
| Pneumonia | 5 | 2020 | 5652 | 0.36 | Why? |
| Interferon-gamma Release Tests | 2 | 2020 | 253 | 0.34 | Why? |
| Acetylcysteine | 2 | 2018 | 255 | 0.30 | Why? |
| Biofilms | 2 | 2018 | 304 | 0.30 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.28 | Why? |
| Pulmonary Disease, Chronic Obstructive | 7 | 2021 | 3832 | 0.28 | Why? |
| Research | 2 | 2018 | 2115 | 0.28 | Why? |
| Pseudomonas aeruginosa | 3 | 2018 | 652 | 0.28 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.27 | Why? |
| Biomedical Research | 3 | 2020 | 5270 | 0.27 | Why? |
| Respiratory Function Tests | 3 | 2020 | 1755 | 0.26 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 3 | 2020 | 1165 | 0.26 | Why? |
| Ultrasonography, Doppler, Duplex | 2 | 2021 | 168 | 0.24 | Why? |
| Hospitalization | 10 | 2021 | 54280 | 0.24 | Why? |
| Italy | 20 | 2021 | 38444 | 0.23 | Why? |
| Cystic Fibrosis | 4 | 2020 | 1104 | 0.23 | Why? |
| Heparin, Low-Molecular-Weight | 2 | 2021 | 1731 | 0.22 | Why? |
| Global Health | 4 | 2019 | 13911 | 0.20 | Why? |
| Hemostatics | 1 | 2021 | 142 | 0.20 | Why? |
| Plankton | 1 | 2018 | 8 | 0.19 | Why? |
| Receptors, Interleukin-1 | 1 | 2020 | 161 | 0.19 | Why? |
| Burkholderia cepacia complex | 1 | 2018 | 18 | 0.19 | Why? |
| Exocrine Pancreatic Insufficiency | 1 | 2018 | 14 | 0.19 | Why? |
| Angiopoietin-1 | 1 | 2018 | 25 | 0.19 | Why? |
| Clinical Governance | 1 | 2018 | 59 | 0.19 | Why? |
| Natural Killer T-Cells | 1 | 2020 | 191 | 0.19 | Why? |
| Latent Tuberculosis | 2 | 2020 | 324 | 0.19 | Why? |
| Lung Volume Measurements | 1 | 2018 | 115 | 0.18 | Why? |
| Chromosomes, Human, Pair 3 | 1 | 2020 | 195 | 0.18 | Why? |
| Stenotrophomonas maltophilia | 1 | 2018 | 63 | 0.18 | Why? |
| Respiratory System Agents | 1 | 2019 | 63 | 0.18 | Why? |
| Tuberculosis | 3 | 2019 | 2895 | 0.17 | Why? |
| Sputum | 4 | 2018 | 1720 | 0.17 | Why? |
| Middle Aged | 38 | 2021 | 270681 | 0.17 | Why? |
| Aged | 36 | 2021 | 215776 | 0.17 | Why? |
| Humans | 77 | 2021 | 930598 | 0.17 | Why? |
| Angiopoietin-2 | 1 | 2018 | 125 | 0.17 | Why? |
| Blood Chemical Analysis | 1 | 2021 | 541 | 0.17 | Why? |
| Lung Transplantation | 2 | 2020 | 1554 | 0.17 | Why? |
| Leukocyte Elastase | 1 | 2017 | 106 | 0.16 | Why? |
| Energy Metabolism | 1 | 2021 | 451 | 0.16 | Why? |
| Pulmonary Ventilation | 1 | 2018 | 152 | 0.16 | Why? |
| Endpoint Determination | 1 | 2019 | 344 | 0.16 | Why? |
| ADAMTS13 Protein | 1 | 2020 | 363 | 0.16 | Why? |
| Metabolome | 1 | 2021 | 624 | 0.16 | Why? |
| Male | 44 | 2021 | 367725 | 0.16 | Why? |
| Female | 45 | 2021 | 380317 | 0.16 | Why? |
| Proteoglycans | 1 | 2017 | 130 | 0.16 | Why? |
| Infertility, Female | 1 | 2018 | 150 | 0.16 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.16 | Why? |
| Cephalosporins | 1 | 2018 | 250 | 0.16 | Why? |
| Patients' Rooms | 1 | 2021 | 675 | 0.16 | Why? |
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 94 | 0.15 | Why? |
| Colistin | 1 | 2018 | 217 | 0.15 | Why? |
| Oximetry | 1 | 2020 | 658 | 0.15 | Why? |
| Picornaviridae Infections | 1 | 2021 | 544 | 0.15 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.15 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.15 | Why? |
| Enterobacteriaceae | 1 | 2019 | 395 | 0.15 | Why? |
| Spirometry | 1 | 2018 | 524 | 0.15 | Why? |
| Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.14 | Why? |
| Drug Synergism | 1 | 2018 | 833 | 0.14 | Why? |
| Venous Thrombosis | 2 | 2021 | 2739 | 0.14 | Why? |
| Acinetobacter baumannii | 1 | 2018 | 378 | 0.14 | Why? |
| Hospital Mortality | 6 | 2021 | 22087 | 0.14 | Why? |
| Cryptogenic Organizing Pneumonia | 1 | 2014 | 35 | 0.14 | Why? |
| Pulmonary Medicine | 2 | 2018 | 706 | 0.14 | Why? |
| von Willebrand Factor | 1 | 2020 | 668 | 0.14 | Why? |
| Drug Therapy | 1 | 2017 | 280 | 0.14 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.14 | Why? |
| Europe | 7 | 2018 | 12702 | 0.14 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.14 | Why? |
| Leukocytes, Mononuclear | 2 | 2021 | 2115 | 0.14 | Why? |
| alpha 1-Antitrypsin | 1 | 2017 | 264 | 0.13 | Why? |
| Cardiotoxicity | 1 | 2017 | 365 | 0.13 | Why? |
| Partial Pressure | 1 | 2014 | 279 | 0.13 | Why? |
| Influenza, Human | 4 | 2021 | 10779 | 0.13 | Why? |
| Natriuretic Peptide, Brain | 1 | 2021 | 1215 | 0.13 | Why? |
| Cross Infection | 5 | 2018 | 8675 | 0.13 | Why? |
| Complement Activation | 1 | 2020 | 949 | 0.13 | Why? |
| Enterobacteriaceae Infections | 1 | 2019 | 529 | 0.13 | Why? |
| Pneumonia, Viral | 12 | 2021 | 243684 | 0.13 | Why? |
| Pseudomonas Infections | 1 | 2018 | 425 | 0.13 | Why? |
| Immunity, Herd | 1 | 2021 | 1011 | 0.12 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.12 | Why? |
| Klebsiella Infections | 1 | 2018 | 466 | 0.12 | Why? |
| Mycobacterium tuberculosis | 2 | 2019 | 1164 | 0.12 | Why? |
| Microbial Sensitivity Tests | 5 | 2019 | 2886 | 0.12 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.12 | Why? |
| Klebsiella pneumoniae | 1 | 2018 | 658 | 0.12 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.12 | Why? |
| Pulmonary Gas Exchange | 1 | 2014 | 414 | 0.11 | Why? |
| Internationality | 3 | 2019 | 3297 | 0.11 | Why? |
| Pneumococcal Vaccines | 1 | 2017 | 571 | 0.11 | Why? |
| Clinical Trials as Topic | 4 | 2019 | 7330 | 0.11 | Why? |
| Refugees | 2 | 2018 | 809 | 0.11 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2021 | 1138 | 0.11 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.11 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.11 | Why? |
| Mutation, Missense | 1 | 2017 | 863 | 0.11 | Why? |
| Prevalence | 8 | 2021 | 25773 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Anti-Inflammatory Agents | 2 | 2020 | 6153 | 0.11 | Why? |
| Respiration Disorders | 1 | 2017 | 526 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2017 | 562 | 0.11 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.11 | Why? |
| Respiratory Tract Infections | 3 | 2021 | 6817 | 0.11 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.10 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2018 | 861 | 0.10 | Why? |
| Peptide Fragments | 1 | 2021 | 2075 | 0.10 | Why? |
| Precision Medicine | 2 | 2018 | 1477 | 0.10 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.10 | Why? |
| Pulmonary Fibrosis | 1 | 2020 | 1068 | 0.10 | Why? |
| Societies, Medical | 4 | 2018 | 6907 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.10 | Why? |
| Blood Platelets | 1 | 2021 | 1704 | 0.10 | Why? |
| Patient Positioning | 1 | 2020 | 1505 | 0.10 | Why? |
| Enzyme Inhibitors | 1 | 2020 | 1881 | 0.10 | Why? |
| Equipment Design | 1 | 2020 | 3095 | 0.10 | Why? |
| Host-Pathogen Interactions | 2 | 2021 | 11041 | 0.10 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.10 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.09 | Why? |
| Oxygen | 3 | 2020 | 3715 | 0.09 | Why? |
| Databases, Factual | 3 | 2018 | 6248 | 0.09 | Why? |
| Lung | 4 | 2019 | 31049 | 0.09 | Why? |
| Biomarkers | 7 | 2021 | 23361 | 0.09 | Why? |
| Thrombosis | 2 | 2021 | 7504 | 0.09 | Why? |
| Severity of Illness Index | 8 | 2020 | 48226 | 0.09 | Why? |
| International Cooperation | 2 | 2019 | 3436 | 0.09 | Why? |
| Cost of Illness | 1 | 2019 | 1903 | 0.09 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.09 | Why? |
| Interleukin-6 | 3 | 2021 | 7522 | 0.09 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.09 | Why? |
| Aged, 80 and over | 12 | 2021 | 88759 | 0.09 | Why? |
| Quality Improvement | 1 | 2020 | 2435 | 0.09 | Why? |
| Observational Studies as Topic | 3 | 2021 | 1887 | 0.09 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.09 | Why? |
| Melphalan | 1 | 2007 | 46 | 0.08 | Why? |
| Prognosis | 6 | 2021 | 32490 | 0.08 | Why? |
| Antineoplastic Agents, Alkylating | 1 | 2007 | 71 | 0.08 | Why? |
| Sarcoma, Ewing | 1 | 2007 | 50 | 0.08 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Pregnancy Outcome | 1 | 2020 | 3803 | 0.08 | Why? |
| Bone Marrow Neoplasms | 1 | 2007 | 60 | 0.08 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.08 | Why? |
| Radiography | 1 | 2014 | 1576 | 0.08 | Why? |
| Blood Gas Analysis | 2 | 2020 | 893 | 0.08 | Why? |
| Logistic Models | 5 | 2018 | 9089 | 0.08 | Why? |
| Pandemics | 11 | 2021 | 389249 | 0.08 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.08 | Why? |
| Transients and Migrants | 1 | 2018 | 1468 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Disease Progression | 6 | 2021 | 13580 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.07 | Why? |
| Myocardium | 1 | 2017 | 2323 | 0.07 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.07 | Why? |
| Respiration, Artificial | 6 | 2021 | 22116 | 0.07 | Why? |
| Intubation, Intratracheal | 1 | 2021 | 3962 | 0.07 | Why? |
| Fluoroquinolones | 1 | 2005 | 235 | 0.07 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Multivariate Analysis | 3 | 2021 | 5440 | 0.06 | Why? |
| Health Services Needs and Demand | 1 | 2018 | 3419 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| Bone Neoplasms | 1 | 2007 | 287 | 0.06 | Why? |
| Cohort Studies | 7 | 2021 | 36005 | 0.06 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.06 | Why? |
| Cough | 1 | 2017 | 4891 | 0.06 | Why? |
| Treatment Failure | 2 | 2021 | 2106 | 0.06 | Why? |
| Health Behavior | 1 | 2021 | 4449 | 0.06 | Why? |
| Delphi Technique | 2 | 2017 | 1257 | 0.06 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.06 | Why? |
| Adult | 15 | 2021 | 244371 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.06 | Why? |
| Clonal Evolution | 1 | 2021 | 55 | 0.06 | Why? |
| Influenza Vaccines | 1 | 2018 | 2941 | 0.06 | Why? |
| Acute Disease | 1 | 2014 | 6029 | 0.06 | Why? |
| Cell Plasticity | 1 | 2021 | 75 | 0.06 | Why? |
| Risk Factors | 6 | 2019 | 71621 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2020 | 196 | 0.05 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.05 | Why? |
| Internet | 1 | 2018 | 6204 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.05 | Why? |
| Glasgow Coma Scale | 1 | 2020 | 249 | 0.05 | Why? |
| Platelet Function Tests | 1 | 2021 | 231 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.05 | Why? |
| Asthma | 1 | 2018 | 4383 | 0.05 | Why? |
| Immunoglobulin Isotypes | 1 | 2021 | 308 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.05 | Why? |
| Complement Membrane Attack Complex | 1 | 2020 | 153 | 0.05 | Why? |
| Multigene Family | 1 | 2020 | 377 | 0.05 | Why? |
| Intubation | 1 | 2021 | 437 | 0.05 | Why? |
| Legionellosis | 1 | 2018 | 31 | 0.05 | Why? |
| Complement C5a | 1 | 2020 | 116 | 0.05 | Why? |
| Pulmonary Emphysema | 1 | 2020 | 122 | 0.05 | Why? |
| Israel | 2 | 2018 | 2751 | 0.05 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 8811 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.05 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.05 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.05 | Why? |
| Deprescriptions | 1 | 2020 | 294 | 0.05 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Chlamydophila pneumoniae | 1 | 2018 | 98 | 0.05 | Why? |
| Drug Resistance, Multiple | 1 | 2019 | 156 | 0.05 | Why? |
| Lymphopenia | 2 | 2020 | 2669 | 0.05 | Why? |
| Masks | 1 | 2021 | 8528 | 0.04 | Why? |
| Total Lung Capacity | 1 | 2017 | 40 | 0.04 | Why? |
| Fatty Acid-Binding Proteins | 1 | 2017 | 93 | 0.04 | Why? |
| Legionella pneumophila | 1 | 2018 | 143 | 0.04 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.04 | Why? |
| Papio | 1 | 2017 | 104 | 0.04 | Why? |
| Stress, Mechanical | 1 | 2017 | 143 | 0.04 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.04 | Why? |
| Hypercapnia | 1 | 2018 | 172 | 0.04 | Why? |
| Survival Analysis | 3 | 2018 | 7592 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.04 | Why? |
| Mycoplasma pneumoniae | 1 | 2018 | 233 | 0.04 | Why? |
| Pulmonary Diffusing Capacity | 1 | 2017 | 191 | 0.04 | Why? |
| Extensively Drug-Resistant Tuberculosis | 1 | 2017 | 87 | 0.04 | Why? |
| Heterozygote | 1 | 2017 | 249 | 0.04 | Why? |
| Respiratory Rate | 1 | 2020 | 691 | 0.04 | Why? |
| Incidence | 4 | 2020 | 25622 | 0.04 | Why? |
| Carbon Monoxide | 1 | 2017 | 167 | 0.04 | Why? |
| Respiration | 1 | 2021 | 729 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.04 | Why? |
| Public Health | 2 | 2018 | 16359 | 0.04 | Why? |
| Cannula | 1 | 2021 | 750 | 0.04 | Why? |
| Vital Capacity | 1 | 2017 | 399 | 0.04 | Why? |
| Calcitonin | 1 | 2017 | 201 | 0.04 | Why? |
| Spain | 3 | 2020 | 15545 | 0.04 | Why? |
| Lower Extremity | 1 | 2021 | 593 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2020 | 1517 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Wakefulness | 1 | 2020 | 598 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.04 | Why? |
| In Vitro Techniques | 1 | 2018 | 1027 | 0.04 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.04 | Why? |
| Rhinovirus | 1 | 2021 | 979 | 0.04 | Why? |
| APACHE | 1 | 2017 | 682 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.03 | Why? |
| Hemostasis | 1 | 2021 | 811 | 0.03 | Why? |
| Oseltamivir | 1 | 2018 | 583 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2020 | 11559 | 0.03 | Why? |
| Forced Expiratory Volume | 1 | 2017 | 632 | 0.03 | Why? |
| European Union | 1 | 2018 | 565 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Macrolides | 1 | 2017 | 369 | 0.03 | Why? |
| Review Literature as Topic | 1 | 2017 | 387 | 0.03 | Why? |
| Tomography, X-Ray Computed | 2 | 2017 | 25144 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2021 | 1289 | 0.03 | Why? |
| Anti-Infective Agents | 1 | 2005 | 1766 | 0.03 | Why? |
| China | 2 | 2020 | 50654 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2021 | 1387 | 0.03 | Why? |
| Enoxaparin | 1 | 2021 | 1064 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2017 | 657 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.03 | Why? |
| Quality of Life | 3 | 2019 | 9820 | 0.03 | Why? |
| North America | 1 | 2017 | 1400 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2020 | 1425 | 0.03 | Why? |
| Geography | 1 | 2018 | 1801 | 0.03 | Why? |
| Biological Specimen Banks | 1 | 2020 | 1142 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.03 | Why? |
| Bronchodilator Agents | 1 | 2017 | 444 | 0.03 | Why? |
| Hemodynamics | 1 | 2020 | 1562 | 0.03 | Why? |
| Troponin T | 1 | 2017 | 771 | 0.03 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.03 | Why? |
| Population Health | 1 | 2018 | 504 | 0.03 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.03 | Why? |
| Ireland | 1 | 2017 | 1456 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2017 | 1475 | 0.03 | Why? |
| Hand Disinfection | 1 | 2021 | 1671 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2017 | 918 | 0.03 | Why? |
| Belgium | 1 | 2017 | 2064 | 0.03 | Why? |
| Asia | 1 | 2017 | 2399 | 0.03 | Why? |
| Cesarean Section | 1 | 2020 | 2089 | 0.02 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.02 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.02 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.02 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.02 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Poland | 1 | 2017 | 2368 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Physical Therapy Modalities | 1 | 2017 | 1090 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Recovery of Function | 1 | 2019 | 2461 | 0.02 | Why? |
| Prone Position | 1 | 2020 | 1861 | 0.02 | Why? |
| Premature Birth | 1 | 2020 | 2151 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2020 | 3088 | 0.02 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.02 | Why? |
| Heart | 1 | 2017 | 1791 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.02 | Why? |
| Heparin | 1 | 2020 | 2600 | 0.02 | Why? |
| South Africa | 1 | 2017 | 3326 | 0.02 | Why? |
| Patient Care Management | 1 | 2018 | 1514 | 0.02 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Bronchitis, Chronic | 1 | 2005 | 15 | 0.02 | Why? |
| United Kingdom | 2 | 2017 | 18046 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2021 | 4418 | 0.02 | Why? |
| Lung Diseases | 1 | 2020 | 2361 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.02 | Why? |
| Pedigree | 1 | 2007 | 502 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Hospitals, University | 1 | 2018 | 4173 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Tracheostomy | 1 | 2018 | 1963 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Australia | 1 | 2017 | 6306 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.02 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.02 | Why? |
| Vulnerable Populations | 1 | 2017 | 3099 | 0.02 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.01 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.01 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.01 | Why? |
| Surgical Procedures, Operative | 1 | 2017 | 2662 | 0.01 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Registries | 1 | 2020 | 12327 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Pain | 1 | 2007 | 1084 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2019 | 22971 | 0.01 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Bacteria | 1 | 2005 | 1897 | 0.01 | Why? |
| Critical Care | 1 | 2017 | 14081 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Child | 1 | 2007 | 70012 | 0.00 | Why? |